267 related articles for article (PubMed ID: 16231967)
1. Single-dose clinical pharmacokinetic studies of gefitinib.
Swaisland HC; Smith RP; Laight A; Kerr DJ; Ranson M; Wilder-Smith CH; Duvauchelle T
Clin Pharmacokinet; 2005; 44(11):1165-77. PubMed ID: 16231967
[TBL] [Abstract][Full Text] [Related]
2. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
[TBL] [Abstract][Full Text] [Related]
3. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
7. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
[TBL] [Abstract][Full Text] [Related]
11. The relative bioavailability of gefitinib administered by granular formulation.
Cantarini MV; Bailey CJ; Collins B; Smith RP
Cancer Chemother Pharmacol; 2008 Jul; 62(2):203-8. PubMed ID: 17909808
[TBL] [Abstract][Full Text] [Related]
12. A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Cantarini MV; Macpherson MP; Marshall AL; Robinson AV; Bailey CJ
Cancer Chemother Pharmacol; 2005 Dec; 56(6):557-62. PubMed ID: 16041611
[TBL] [Abstract][Full Text] [Related]
13. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
[TBL] [Abstract][Full Text] [Related]
14. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
15. Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Videla S; Lahjou M; Guibord P; Xu Z; Tolrà C; Encina G; Sicard E; Sans A
Drugs R D; 2012 Dec; 12(4):217-25. PubMed ID: 23230999
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers.
Encina G; Encabo M; Escriche M; Lahjou M; Sicard E; Smith K; Gascon N; Plata-Salamán C; Videla S
Clin Drug Investig; 2018 Sep; 38(9):819-827. PubMed ID: 30008052
[TBL] [Abstract][Full Text] [Related]
18. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Furman WL; Navid F; Daw NC; McCarville MB; McGregor LM; Spunt SL; Rodriguez-Galindo C; Panetta JC; Crews KR; Wu J; Gajjar AJ; Houghton PJ; Santana VM; Stewart CF
J Clin Oncol; 2009 Sep; 27(27):4599-604. PubMed ID: 19687340
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
